Gastritis Market

Table of Content

1. INTRODUCTION
   1. Study Assumptions and Market Definition
   2. Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
   1. Market Overview
   2. Market Drivers
      1. Increased Gastrointestinal Disorders
   3. Market Restraints
      1. Medication Side Effects and Risks
      2. Limited Efficacy of Standard Treatments
   4. Market Opportunities
      1. High-end Efficiency of Biologics
   5. Market Trends
      1. Shift towards Personalized Medicine
      2. Soaring Adoption of Non-invasive Diagnostic Technologies
5. MARKET SEGMENTATION
   1. By Treatment
      1. Acid Blocking Medications
      2. Prevacid 24HR (lansoprazole)
      3. Nexium 24HR
      4. Acid Reducing Medications
      5. Nexium
      6. Prevacid
      7. Antacids
      8. Aluminium hydroxide
      9. Magnesium carbonate
      10. Antibiotics
      11. Amoxicillin
      12. Doxycycline
      13. Others
   2. By Type
      1. Acute Gastritis
      2. Chronic Gastritis
      3. Erosive Gastritis
      4. Non-Erosive Gastritis
   3. By Route of Administration
      1. Oral
      2. Parenteral
   4. By End-Users
      1. Hospitals
      2. Homecare
      3. Specialty Clinics
      4. Others
   5. By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Online Pharmacies
      4. Others
   6. By Key Geographic Regions
      1. North America
         1. United States
         2. Canada
         3. Mexico
      2. Europe
         1. Germany
         2. United Kingdom
         3. France
         4. Italy
         5. Spain
         6. Rest of Europe
      3. Asia Pacific
         1. China
         2. Japan
         3. India
         4. Australia
         5. South Korea
         6. Rest of Asia Pacific
      4. Middle East and Africa
         1. GCC
         2. South Africa
         3. Rest of Middle East and Africa
      5. South America
         1. Brazil
         2. Argentina
         3. Rest of South America
6. COMPETITIVE LANDSCAPE
   1. Company Profile
      1. Amgen Inc. (U.S.)
      2. AstraZeneca (U.K.)
      3. Dr. Reddy's Laboratories Ltd (India)
      4. Endo International plc (Ireland)
      5. F. Hoffmann-La Roche Ltd. (Switzerland)
      6. GSK plc (U.K.)
      7. Johnson & Johnson Private Limited (U.S.)
      8. Lupin (India)
      9. Lilly (U.S.)
      10. Merck & Co., Inc. (U.S.)
      11. Mylan N.V. (U.S.)
      12. Novartis AG (Switzerland)
      13. Pfizer Inc. (U.S.)
      14. Sun Pharmaceutical Industries Ltd. (India)
      15. Sanofi (France)
      16. Teva Pharmaceutical Industries Ltd. (Israel)
      17. Zydus Group (India)
   2. MARKET OPPORTUNITIES AND FUTURE TRENDS

Frequently Asked Questions

Q.1. What is the projected market value of the global Gastritismarket?

The global market of Gastritis is projected to reach USD 259.69 Mn by 2033.

Q.2. What is the estimated growth rate (CAGR) of the global Gastritismarket?

The global Gastritis market has an estimated annual growth rate of 4.0%. 

Q.3. What are the recent trends of Gastritismarket?

Shift towards personalized medicine and soaring adoption of non-invasive diagnostic technologiesare some of the major trends of the market that is projected to boost the market growth in the near future.

Q.4. Which are the top companies to hold the market share in Gastritis?

The major companies profiled in this report include Amgen Inc. (U.S.), AstraZeneca (U.K.), Dr. Reddy's Laboratories Ltd (India), Endo International plc (Ireland), F. Hoffmann-La Roche Ltd. (Switzerland), GSK plc (U.K.), Johnson & Johnson Private Limited (U.S.), Lupin (India), Lilly (U.S.), Merck & Co., Inc. (U.S.), Mylan N.V. (U.S.), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Sanofi (France), Teva Pharmaceutical Industries Ltd. (Israel), Zydus Group (India), among others. 

Q.5. Which region is estimated to held highest CAGR inGastritismarket?

North America is estimated to hold biggest share in the market for Gastritis.